de David Shaw Amicus Therapeutics FOLD Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Vender |
-488,098
| Cerradas | -USD 7.06 M | – | 4995 |
|
|
2026
Q1 | USD 7.06 M | Vender |
488,098
-1,060,905
| -68% | -USD 15.2 M | ﹤0.01% | 1914 |
|
|
2025
Q4 | USD 22.1 M | Vender |
1,549,003
-2,319,207
| -60% | -USD 22.8 M | 0.01% | 1192 |
|
|
2025
Q3 | USD 30.5 M | Vender |
3,868,210
-2,494,040
| -39% | -USD 17.7 M | 0.02% | 911 |
|
|
2025
Q2 | USD 36.5 M | Comprar |
6,362,250
+4,071,968
| +178% | +USD 26.3 M | 0.03% | 718 |
|
|
2025
Q1 | USD 18.7 M | Comprar |
2,290,282
+729,872
| +47% | +USD 6.75 M | 0.02% | 986 |
|
|
2024
Q4 | USD 14.7 M | Comprar |
1,560,410
+889,968
| +133% | +USD 9.25 M | 0.01% | 1237 |
|
|
2024
Q3 | USD 7.16 M | Comprar |
670,442
+581,167
| +651% | +USD 6.33 M | 0.01% | 1667 |
|
|
2024
Q2 | USD 886 k | Vender |
89,275
-35,751
| -29% | -USD 367 k | ﹤0.01% | 3271 |
|
|
2024
Q1 | USD 1.47 M | Vender |
125,026
-161,198
| -56% | -USD 2.06 M | ﹤0.01% | 2841 |
|
|
2023
Q4 | USD 4.06 M | Vender |
286,224
-73,967
| -21% | -USD 840 k | ﹤0.01% | 2077 |
|
|
2023
Q3 | USD 4.38 M | Vender |
360,191
-771,735
| -68% | -USD 10 M | ﹤0.01% | 1922 |
|
|
2023
Q2 | USD 14.2 M | Vender |
1,131,926
-519,671
| -31% | -USD 6.17 M | 0.01% | 1088 |
|
|
2023
Q1 | USD 18.3 M | Vender |
1,651,597
-581,728
| -26% | -USD 7.17 M | 0.02% | 953 |
|
|
2022
Q4 | USD 27.3 M | Vender |
2,233,325
-670,171
| -23% | -USD 7.54 M | 0.03% | 721 |
|
|
2022
Q3 | USD 30.3 M | Vender |
2,903,496
-65,240
| -2% | -USD 727 k | 0.04% | 623 |
|
|
2022
Q2 | USD 31.9 M | Vender |
2,968,736
-75,702
| -2% | -USD 623 k | 0.04% | 615 |
|
|
2022
Q1 | USD 28.8 M | Comprar |
3,044,438
+279,142
| +10% | +USD 2.62 M | 0.03% | 795 |
|
|
2021
Q4 | USD 31.9 M | Comprar |
2,765,296
+573,279
| +26% | +USD 6.39 M | 0.03% | 791 |
|
|
2021
Q3 | USD 20.9 M | Vender |
2,192,017
-766,130
| -26% | -USD 7.84 M | 0.02% | 993 |
|
|
2021
Q2 | USD 28.5 M | Vender |
2,958,147
-1,456,829
| -33% | -USD 14.2 M | 0.02% | 820 |
|
|
2021
Q1 | USD 43.6 M | Vender |
4,414,976
-2,664,620
| -38% | -USD 41.2 M | 0.04% | 546 |
|
|
2020
Q4 | USD 163 M | Vender |
7,079,596
-264,668
| -4% | -USD 5.41 M | 0.15% | 137 |
|
|
2020
Q3 | USD 104 M | Comprar |
7,344,264
+296,215
| +4% | +USD 4.32 M | 0.11% | 211 |
|
|
2020
Q2 | USD 106 M | Comprar |
7,048,049
+1,482,310
| +27% | +USD 18.1 M | 0.13% | 160 |
|
|
2020
Q1 | USD 51.4 M | Comprar |
5,565,739
+1,739,698
| +45% | +USD 16.5 M | 0.08% | 283 |
|
|
2019
Q4 | USD 37.3 M | Comprar |
3,826,041
+1,034,197
| +37% | +USD 9.47 M | 0.04% | 517 |
|
|
2019
Q3 | USD 22.4 M | Comprar |
2,791,844
+644,441
| +30% | +USD 6.99 M | 0.03% | 721 |
|
|
2019
Q2 | USD 26.8 M | Comprar |
2,147,403
+1,146,777
| +115% | +USD 14.6 M | 0.03% | 612 |
|
|
2019
Q1 | USD 13.6 M | Comprar |
1,000,626
+109,646
| +12% | +USD 1.34 M | 0.02% | 921 |
|
|
2018
Q4 | USD 8.54 M | Vender |
890,980
-1,509,694
| -63% | -USD 16.6 M | 0.01% | 1188 |
|
|
2018
Q3 | USD 29 M | Vender |
2,400,674
-1,324,370
| -36% | -USD 18.5 M | 0.03% | 605 |
|
|
2018
Q2 | USD 58.2 M | Vender |
3,725,044
-694,735
| -16% | -USD 10.5 M | 0.08% | 323 |
|
|
2018
Q1 | USD 66.5 M | Comprar |
4,419,779
+1,963,566
| +80% | +USD 29.9 M | 0.09% | 271 |
|
|
2017
Q4 | USD 35.3 M | Vender |
2,456,213
-2,049,287
| -45% | -USD 28.2 M | 0.05% | 449 |
|
|
2017
Q3 | USD 67.9 M | Comprar |
4,505,500
+435,205
| +11% | +USD 5.76 M | 0.1% | 239 |
|
|
2017
Q2 | USD 41 M | Comprar |
4,070,295
+488,357
| +14% | +USD 3.93 M | 0.07% | 343 |
|
|
2017
Q1 | USD 25.5 M | Comprar |
3,581,938
+1,251,339
| +54% | +USD 7.91 M | 0.04% | 479 |
|
|
2016
Q4 | USD 11.6 M | Comprar |
2,330,599
+31,528
| +1% | +USD 218 k | 0.02% | 873 |
|
|
2016
Q3 | USD 17 M | Vender |
2,299,071
-476,522
| -17% | -USD 3.22 M | 0.03% | 645 |
|
|
2016
Q2 | USD 15.2 M | Vender |
2,775,593
-127,879
| -4% | -USD 894 k | 0.03% | 655 |
|
|
2016
Q1 | USD 24.5 M | Vender |
2,903,472
-522,024
| -15% | -USD 3.7 M | 0.04% | 463 |
|
|
2015
Q4 | USD 33.2 M | Comprar |
3,425,496
+2,030,981
| +146% | +USD 18.3 M | 0.05% | 428 |
|
|
2015
Q3 | USD 19.5 M | Vender |
1,394,515
-236,209
| -14% | -USD 3.7 M | 0.03% | 627 |
|
|
2015
Q2 | USD 23.1 M | Vender |
1,630,724
-938,602
| -37% | -USD 11.3 M | 0.03% | 588 |
|
|
2015
Q1 | USD 28 M | Vender |
2,569,326
-486,838
| -16% | -USD 4.29 M | 0.04% | 492 |
|
|
2014
Q4 | USD 25.4 M | Comprar |
3,056,164
+1,550,432
| +103% | +USD 10.6 M | 0.03% | 605 |
|
|
2014
Q3 | USD 8.96 M | Comprar |
1,505,732
+921,150
| +158% | +USD 4.83 M | 0.01% | 1158 |
|
|
2014
Q2 | USD 1.95 M | Vender |
584,582
-76,208
| -12% | -USD 179 k | ﹤0.01% | 2324 |
|
|
2014
Q1 | USD 1.37 M | Comprar |
660,790
+53,742
| +9% | +USD 134 k | ﹤0.01% | 2760 |
|
|
2013
Q4 | USD 1.43 M | Comprar |
607,048
+187,355
| +45% | +USD 411 k | ﹤0.01% | 2846 |
|
|
2013
Q3 | USD 974 k | Comprar |
419,693
+48,832
| +13% | +USD 123 k | ﹤0.01% | 3063 |
|
|
2013
Q2 | USD 864 k | Comprar |
+370,861
| Nuevas | +USD 1.14 M | ﹤0.01% | 2838 |
|
Otros fondos que tienen FOLD en su cartera
Posición de David Shaw en FOLD: resumen de T2 2026
David Shaw cerró por completo su posición en Amicus Therapeutics (FOLD) en T2 2026, liquidando una posición de 488,098 acciones por un valor estimado de USD 7.06 M.
David Shaw reportó por primera vez una posición en FOLD en T2 2013 y la mantuvo durante 52 trimestres. La posición alcanzó su máximo de USD 163 M en T4 2020. Al cierre de T2 2026, 2 fondos que sigue Wall St. Rank mantienen una posición en FOLD.
- David Shaw reportó que ya no tenía una posición en Amicus Therapeutics al cierre de T2 2026, después de venderla por completo durante el trimestre.
- David Shaw vendió 488,098 acciones de Amicus Therapeutics en T2 2026, por un valor estimado de USD 7.06 M.
- David Shaw reportó por primera vez una posición en Amicus Therapeutics en T2 2013 y la mantuvo durante 52 trimestres.
- La posición de David Shaw en Amicus Therapeutics alcanzó su máximo de USD 163 M en T4 2020.
- Al cierre de T2 2026, 2 fondos que sigue Wall St. Rank tenían Amicus Therapeutics en cartera.
Según el Informe 13F de D.E. Shaw & Co correspondiente a T2 2026, presentado el 14 ago 2026.